About Velosbio inc.
Velosbio Inc. is a biotechnology company that is dedicated to developing innovative cancer therapies. The company was founded in 2017 and is headquartered in San Diego, California. Velosbio's mission is to improve the lives of cancer patients by developing targeted therapies that are more effective and less toxic than traditional chemotherapy.
Velosbio's team of experienced scientists and researchers are focused on discovering new treatments for cancer by targeting specific proteins that are overexpressed in tumor cells. By targeting these proteins, Velosbio hopes to develop therapies that can selectively kill cancer cells while sparing healthy cells.
One of Velosbio's most promising drug candidates is VLS-101, a monoclonal antibody that targets ROR1, a protein that is overexpressed in many types of cancer. Preclinical studies have shown that VLS-101 can effectively kill tumor cells while leaving healthy cells unharmed.
In addition to VLS-101, Velosbio has several other drug candidates in development, including VLS-102 which targets ROR2 and VLS-103 which targets DLL3. These drugs have the potential to treat a wide range of cancers including breast cancer, lung cancer, and pancreatic cancer.
Velosbio has received significant funding from venture capital firms including Sofinnova Ventures and Pappas Capital as well as from strategic partners such as Merck & Co., Inc., one of the world's leading pharmaceutical companies.
The partnership with Merck & Co., Inc. provides Velosbio with access to resources such as expertise in clinical development and regulatory affairs as well as financial support for its research programs. This collaboration will help accelerate the development of Velobio's drug candidates and bring them closer to market approval.
Velobio has also established partnerships with leading academic institutions such as MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center to further advance its research programs.
In conclusion, Velobio Inc. is a biotechnology company that is dedicated to developing innovative cancer therapies. With its experienced team of scientists and researchers, promising drug candidates, and strategic partnerships with leading pharmaceutical companies and academic institutions, Velobio is well-positioned to make significant contributions to the fight against cancer.